SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
Clinical trial NCT06676722 · RECRUITING
Trial details
- NCT number
- NCT06676722
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-05
- Primary completion
- 2026-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.